Press Releases & HAE News

June 4th, 2024
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

May 31st, 2024
KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema

May 31st, 2024
Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema

May 13th, 2024
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses

May 8th, 2024
The US Hereditary Angioedema Association Scientific Registry: hereditary angioedema demographics, disease severity, and comorbidities

May 8th, 2024
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update

April 10th, 2024
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

April 4th, 2024
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

April 4th, 2024
Most HAE patients surveyed say they can predict swelling attacks

March 21st, 2024
Study Data Suggests Sustained Safety, Efficacy of Lanadelumab in Adolescents With HAE

March 18th, 2024
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas

March 18th, 2024
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

February 27th, 2024
KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

February 22nd, 2024
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting

February 15th, 2024
Sebetralstat found effective in trial as on-demand treatment for HAE

February 5th, 2024
Single dose of NTLA-2002 seen to reduce monthly HAE attacks 95%

February 1st, 2024
CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema

February 1st, 2024
Angiodema: Gene therapy blocks painful hereditary disorder

January 31st, 2024
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

January 22nd, 2024
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks

January 12th, 2024
The road less traveled highlights the importance of being informed

January 11th, 2024
Long-term use of attenuated androgens may increase health risks

December 26th, 2023
Switching from androgens to Orladeyo reduces HAE swelling attacks

December 21st, 2023
Long-term Orladeyo safe, effective in HAE patients: Trial data

December 18th, 2023
Garadacimab up for approval as HAE therapy in US, Europe

December 18th, 2023
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema

December 6th, 2023
Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

December 4th, 2023
Phase 3 trial of sebetralstat meets targeted number of treated attacks

November 30th, 2023
STAR-0215 shows promise as HAE treatment in new Phase 1 trial data

November 27th, 2023
HAE attacks start resolving in under 30 minutes with PHVS416 in trial

November 23rd, 2023
Examining the Impact of the COVID-19 Pandemic on Individuals Affected by Hereditary Angioedema Type I and Type II

November 15th, 2023
Two-Year Analysis of the Donidalorsen Phase 2 Open-Label Extension Study in Patients With Hereditary Angioedema

November 13th, 2023
KalVista Pharmaceuticals Announces Phase 3 KONFIDENT Trial Milestone Achieved

November 13th, 2023
Fewer HAE attacks, life quality gains seen with donidalorsen at 2 years

November 9th, 2023
Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema

October 26th, 2023
Despite preventive treatment, HAE patients require on-demand care

October 12th, 2023
Patient feedback helps in design of Phase 3 trial of oral sebetralstat

October 7th, 2023
Hereditary Angioedema patient experiences of medication use and emergency care

September 22nd, 2023
When periods of good health don’t lead to needed rest

August 31st, 2023
Orladeyo effective in 3 people with HAE of unknown origin

August 17th, 2023
FDA approves new generic version of Firazyr for HAE

August 14th, 2023
Patient enrollment for deucrictibant CHAPTER-1 trial completed

August 11th, 2023
Why there’s power in sharing our angioedema stories

August 10th, 2023
Phase 3 trial of gene-editing therapy NTLA-2002 for HAE slated for 2024

July 27th, 2023
HAE patients can see early signs of attacks, need for prompt treatment

July 27th, 2023
HAE patients can see early signs of attacks, need for prompt treatment

July 20th, 2023
Long-Acting Plasma Kallikrein Inhibitor Gets Fast Track Status for Hereditary Angioedema

July 17th, 2023
BioCryst to Participate in the 2023 US HAEA National Summit

July 14th, 2023
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 US HAEA National Summit

July 14th, 2023
I finally understand my daughter’s fear of missing out

July 13th, 2023
Long-term Takhzyro treatment linked to lower US healthcare costs

June 30th, 2023
How schools (too often) need to be educated about HAE

June 26th, 2023
Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE

June 23rd, 2023
Dealing with my daughter’s HAE led to an epiphany about my mother

June 22nd, 2023
PHVS416 found to quickly ease HAE swelling symptoms in trial

June 15th, 2023
9 of 10 HAE patients attack free with NTLA-2002, gene-editing therapy

June 11th, 2023
Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

June 2nd, 2023
The remedy to feeling small is finding your rare disease community

June 1st, 2023
Positive donidalorsen late-stage clinical progress in HAE announced by Ionis

June 1st, 2023
Ionis announces positive donidalorsen late-stage clinical progress in HAE

May 26th, 2023
How the space-time continuum is affected by caregiving

May 19th, 2023
How being an HAE caregiver led me to awareness and advocacy

May 11th, 2023
Plasma donors desperately needed to save lives

May 9th, 2023
Dosing of HAE gene-editing therapy NTLA-2002 begins in Phase 2 study

May 4th, 2023
Prodromal Symptoms of Hereditary Angioedema (HAE) attacks: a patient survey in UK & Spain

May 4th, 2023
Under-the-skin injections found to ease angioedema in pregnancy

May 1st, 2023
Orladeyo helps HAE patients spend more days attack-free: Trial analysis

April 28th, 2023
Ellington mother and son talk about their battle with hereditary angioedema

April 28th, 2023
How kid logic complicates effective HAE treatment

April 24th, 2023
US health insurance problems affect well-being of HAE patients: Survey

April 22nd, 2023
Managing Diagnosis, Treatment, and Burden of Disease in Hereditary Angioedema Patients with Normal C1-Esterase Inhibitor

April 21st, 2023
Providers urged to do more to help patients access care for hereditary angioedema

April 14th, 2023
The frustrating conversations with people who don’t understand HAE

April 13th, 2023
Takhzyro linked to long-term quality of life gains in HAE study

April 10th, 2023
PHVS416 shows promise in treating HAE swelling attacks: Trial data

April 10th, 2023
FDA Clears First Study of CRISPR Gene-Editing in Human Patients

April 7th, 2023
Learning to embrace my support team after an HAE diagnosis

April 6th, 2023
Multiple obstacles make hereditary angioedema diagnosis, treatment difficult

April 6th, 2023
Preventive therapy found to reduce number, not severity of HAE attacks

April 5th, 2023
Survey of Allergists/Immunologists Reveals Management of Hereditary Angioedema Differs by Region

April 3rd, 2023
Poorly controlled HAE carries heavy burden, affecting life quality

April 1st, 2023
‘PEEPbra’ sculpture aims to raise awareness about rare diseases during annual PEEPshow in Westminster

March 24th, 2023
Oh, the relief that comes when an educated expert arrives to help

March 20th, 2023
Diagnosing and treating HAE most challenging across rural US

March 18th, 2023
Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC

March 16th, 2023
Insurance delays, denials negatively impact patients with hereditary angioedema

March 16th, 2023
CSL Behring to seek approval of garadacimab this year

March 6th, 2023
Phase 2 trial of NTLA-2002, HAE gene-editing therapy, to enroll in US

March 2nd, 2023
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)

February 28th, 2023
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

February 27th, 2023
Debajyoti Ghosh, PhD: Potential Benefits of Treating Hereditary Angioedema Early Symptoms

February 27th, 2023
Genetic analysis reveals recurrent HAE with normal C1-INH: Study

February 26th, 2023
CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing

February 24th, 2023
How to guard against the crash after doing too much

February 22nd, 2023
HAE exacerbations secondary to insurance barriers: A common, yet avoidable, trigger

February 20th, 2023
Survey of US doctors estimates prevalence of HAE-nl-C1INH

February 17th, 2023
The unsung heroes of hereditary angioedema treatment

February 16th, 2023
Consider Hereditary Angioedema in the Differential Diagnosis for Unexplained Recurring Abdominal Pain

February 16th, 2023
Identifying the Zebras: Key Insights on Chronic Abdominal Pain in HAE

February 14th, 2023
KalVista Pharmaceuticals Provides Progress Updates on Sebetralstat Development

February 9th, 2023
Phase 1b/2 trial of STAR-0215 is now enrolling HAE patients

February 7th, 2023
New Chief Takes the Helm at the Life Raft Group as GIST Research Continues to Expand

February 3rd, 2023
U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Use of TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older

February 1st, 2023
Bright Ideas for Rare Disease Day 2023

January 30th, 2023
I wrote about high-priced drugs for years. Then my toddler needed one.

January 27th, 2023
Why Complicate Things When There’s a Simple Explanation?

January 26th, 2023
BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema

January 25th, 2023
Ground-breaking gene-editing treatment leaves patient feeling like they have 'a new body'

January 24th, 2023
A Rare Public Health Challenge

January 23rd, 2023
Bowel Surgery Necessary for HAE Patient After Therapy Fails

January 20th, 2023
Ignoring the Symptoms of Illness That Have Always Been There

January 16th, 2023
‘A magic wand’: World-first NZ gene-editing trial may offer cure for debilitating disorder

January 15th, 2023
Hereditary Angioedema with Normal C1 Esterase Inhibitor Refractory to Long-Term Prophylaxis: A Case Report

January 13th, 2023
How Endless Circles Can Lead to Frustration

January 12th, 2023
6 New Angioedema Centers Now Part of ACARE Global Network

January 6th, 2023
The Most Important New Year’s Resolution for Caregivers

December 24th, 2022
Dealing with a life-changing illness: Bringing awareness can sometimes be the best medicine

December 23rd, 2022
OK, Class! Time to Open Your Calendars and Review the Year

December 22nd, 2022
Airway Angioedema Triggered by ACE Inhibitor Not Eased by Berinert

December 15th, 2022
Astria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects

December 12th, 2022
Severe Recurrent Abdominal Pain Leads to HAE Type 1 Diagnosis: Case

December 9th, 2022
Detecting Hereditary Angioedema Symptoms Early to Mitigate Flares

December 2nd, 2022
After Suffering a Crippling Loss, Keep Going

November 28th, 2022
Most HAE Patients Treated With Donidalorsen for Year Attack Free

November 25th, 2022
The Best Way to Accentuate the Positive

November 18th, 2022
Why I Fear Sending My Daughter to Slumber Parties

November 17th, 2022
Most HAE Patients Attack-free After Gene-editing Therapy NTLA-200

November 12th, 2022
Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting

November 11th, 2022
Sharing Duties as a Family Caregiver Is Like Losing a Security Blanket

November 10th, 2022
BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction After Beginning ORLADEYO® (berotralstat), Regardless of Prior Prophylactic Therapy

November 10th, 2022
Treatment using CRISPR genome editing alleviates swelling attacks in hereditary angioedema patients

November 9th, 2022
CRISPR Treatment Slows Swelling in Hereditary Angioedema Patients

November 4th, 2022
We Don’t Know What We Don’t Know — But We Can Learn

October 31st, 2022
KalVista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema

October 27th, 2022
Pregnancy Not Linked to Worse Disease in Women With HAE: Study

October 24th, 2022
Takhyrzo Found to Be Effective HAE Treatment Across Minority Groups

October 21st, 2022
On Bad Weeks, You Need the Best Team Ever

October 20th, 2022
Man’s Only Symptom of HAE Type 2 Is Abdominal Pain: Case Report

October 19th, 2022
KalVista Pharmaceuticals Announces Publications in the Journal of Medicinal Chemistry and Xenobiotica for Sebetralstat

October 17th, 2022
2 New US CSL Plasma Collection Centers Open to Meet Growing Need

October 14th, 2022
I’m Not in the Business of Raising Champions

October 10th, 2022
FDA Decision Due Next Year on Takhzyro for Children as Young as 2

October 5th, 2022
U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Use of TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older

September 26th, 2022
A challenging diagnosis: hereditary angioedema presenting during pregnancy

September 23rd, 2022
The Importance of Staying Aware So That Rare Doesn’t Surprise You

September 22nd, 2022
Takhzyro Use Resulted in Prolonged Dosing Intervals, Fewer Treatment

September 19th, 2022
NTLA-2002 Gene Therapy Safely Prevents HAE Attacks: Trial Data

September 16th, 2022
Coming to Terms With Unrealistic Expectations After an HAE Diagnosis

September 16th, 2022
Intellia offers first look at CRISPR drug for rare swelling disorder

September 15th, 2022
The Interplay of COVID-19 and Hereditary Angioedema: Preventing an Acute Attack

September 9th, 2022
Even Those Things We Love Can Become an Instant Problem

September 6th, 2022
Investigational CRISPR Therapy Gets Orphan Drug Status for Hereditary Angioedema

September 2nd, 2022
Past Experiences Make Me Wonder About My Daughter’s Future Friendships

August 26th, 2022
To Treat Special Needs, an Average Babysitter Just Isn’t Enough

August 25th, 2022
Garadacimab Effective at Preventing HAE Attacks, Phase 3 Trial Shows

August 22nd, 2022
Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S.

August 19th, 2022
‘Back in the Car, but Out of the Tree’: Addressing Medical Fears With Compassion

August 18th, 2022
CSL gets positive results for preventive treatment in patients with hereditary angioedema

August 17th, 2022
Meet the Expert: Focus on HAE

August 16th, 2022
New Explorer’s career plan? Advocate for those fighting rare diseases

August 16th, 2022
Former high school track athlete in north metro battling rare disease

August 12th, 2022
The Importance of Finding Space for Your Passions

August 11th, 2022
Case Highlights Importance of Distinguishing Types of Angioedema

August 5th, 2022
The Experience of Living in Denial, From Soda to a Diagnosis

August 4th, 2022
Astria Therapeutics Announces Initiation Of Phase 1a Trial Of STAR-0215, A Monoclonal Antibody Inhibitor Of Plasma Kallikrein For Treatment Of Hereditary Angioedema

August 4th, 2022
PAR1 Protein May Be Target for HAE Treatment

July 25th, 2022
Ruconest Works for 1 in 6 With Idiopathic Angioedema in Pilot Study

July 25th, 2022
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema

July 18th, 2022
Firazyr or Icatibant May, With Caution, Be Safe While Breastfeeding

July 15th, 2022
Understanding My Own Weird Habits Allowed Me to Help My Daughter Relax

July 10th, 2022
A Hollywood ending: How one woman took control of her rare disease and achieved her dream

July 1st, 2022
How Our Daughter Defines Normal With Hereditary Angioedema

July 1st, 2022
Takeda targets younger HAE patients with Phase 3 data for Takhzyro

June 30th, 2022
Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years

June 30th, 2022
Symptoms of HAE Can Occur Without Swelling Attack: Study

June 20th, 2022
Firazyr Safe for Attacks in Patients With Normal C1-INH Activity

June 17th, 2022
Planning Road Trips Leads to Worry — and Who Needs That?

June 10th, 2022
Navigating Love and Relationships While Caring for a Sick Child

June 9th, 2022
2 More Countries Approve Orladeyo for Preventing HAE Attacks

June 8th, 2022
KalVista Pharmaceuticals Presents Promising Preclinical Data for Oral Factor XIIa Inhibitor Program

June 1st, 2022
Prophylactic therapy with subcutaneous C1 inhibitor reduces hereditary angioedema attacks

May 25th, 2022
Acute HAE Attack Seen With Rare Stroke-like Symptoms: Case Report

May 23rd, 2022
Use of Haegarda Reduces Swelling Attack Rate, Rescue Medication Use

May 19th, 2022
KalVista’s HAE Treatment KVD900 Now Called Sebetralstat

May 17th, 2022
KalVista Pharmaceuticals Announces Non-Proprietary Name Selection for KVD900

May 9th, 2022
Dosing Complete in Phase 1/2 1st Group of NTLA-2002 Trial for HAE

April 18th, 2022
Takeda’s TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States

April 15th, 2022
Because the Other Kids Get Sick, Too

April 12th, 2022
Takeda Touts Positive Pediatric Data in Competitive HAE Space

April 11th, 2022
The Use of 6 Warning Signs May Aid in Improving C1-INH-HAE Diagnosis

April 5th, 2022
The healing power of art

March 30th, 2022
HAEi Global Perspectives Magazine Spring 2022

March 25th, 2022
How I Stopped Forgetting to Remember

March 21st, 2022
Swelling Attacks Down, Quality of Life Up in Donidalorsen Phase 2 Trial

March 18th, 2022
Coming to Terms With Caregiver’s Guilt

March 17th, 2022
Inhibition of Prekallikrein for Hereditary Angioedema

March 17th, 2022
3D Analysis of Facial Features May Help Treat, Diagnose HAE

March 16th, 2022
Antisense Drug Slashed Hereditary Angioedema Attacks in Small Study

March 16th, 2022
Ionis announces publication of positive Phase 2 data for donidalorsen in New England Journal of Medicine

March 14th, 2022
Astria Anticipates Trial of STAR-0215 in Healthy Volunteers This Year

March 10th, 2022
Takhzyro Found Safe, Effective for HAE Over Long Term in Real-world Study

March 7th, 2022
Orladeyo Shown to Prevent Attacks and Improve Quality of Life in Trial

March 7th, 2022
KalVista Pharmaceuticals Announces Initiation of KVD900 Phase 3 KONFIDENT Clinical Trial

March 4th, 2022
We Forgot to Tell Our Daughter About Her Diagnosis

February 28th, 2022
Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients

February 25th, 2022
The Tale of Two Truths

February 24th, 2022
BioCryst's Orladeyo Shows Long Term Benefit With Sustained Reductions in Attack Rates

February 21st, 2022
Enrollment Opens in HAERMONY Trial to Test HAE Gene Therapy

February 18th, 2022
Step-ball-Change Into Butterfly Needles

February 14th, 2022
Takhzyro in More Convenient Prefilled Syringe Approved in US for HAE

February 10th, 2022
Takeda Receives U.S. FDA Approval for Prefilled Syringe Presentation of TAKHZYRO (lanadelumab-flyo) for Use as a Preventive Treatment for Hereditary Angioedema Attacks

February 10th, 2022
Berinert Prevents Acute Swelling in HAE Patient After Oral Surgery

February 7th, 2022
Changes in Gut Microbiota May Contribute to HAE Attacks

January 27th, 2022
KVD900 Rapidly Suppresses Kallikrein, Phase 1 Studies Show

January 24th, 2022
KalVista Pharmaceuticals Announces Publication of Oral HAE Therapy KVD900 Phase 1 Data in Journal of Allergy and Clinical Immunology

January 24th, 2022
Warning Symptoms May Foretell HAE Attacks, Study Finds

January 20th, 2022
Study shows advances in treatments for patients with angioedema in Puerto Rico

January 20th, 2022
Care May Prevent Airway Swelling in HAE Patients During Surgery

January 17th, 2022
US Patients Underreport Burden of HAE to Their Doctors, Study Says

January 10th, 2022
New Gene Mutation Linked to HAE Type 1 Identified in Spanish Family

January 7th, 2022
An anesthetic experience of hereditary angioedema type I patient undertook total laparoscopic hysterectomy - A case report -

December 16th, 2021
An Evidence Based Therapeutic Approach To Hereditary And Acquired Angioedema

December 16th, 2021
Trial of HAE Gene-editing Therapy NTLA-2002 Doses Its First Patient

December 9th, 2021
Highly Unpredictable Rate of Annual Attacks Seen in Certain Patients

December 7th, 2021
COVID-19 and hereditary angioedema: Incidence, outcomes, and mechanistic implications

December 2nd, 2021
How do patients and physicians communicate about hereditary angioedema in the United States?

November 15th, 2021
Phase 3 Study of Oral KVD900 as On-Demand Therapy Likely in 2022

November 11th, 2021
Orladeyo Sustainably Lowers HAE Attack Rates, Trial Data Show

November 10th, 2021
KalVista Pharmaceuticals Provides Progress Update on KVD900 for Oral On-Demand Treatment of Hereditary Angioedema

November 10th, 2021
HAE Still Drawing Attention From Drugmakers

November 8th, 2021
Patient-collected Blood Samples May Help Predict Acute HAE Attacks

November 7th, 2021
Phase 2 study results of Ionis' novel antisense treatment for hereditary angioedema to be presented at ACAAI annual meeting

October 26th, 2021
BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

October 25th, 2021
Patients Say They Want to Switch to Less Frequent Therapies

October 6th, 2021
Optimization of care for patients with hereditary angioedema living in rural areas

October 6th, 2021
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

October 4th, 2021
CAMP4 Platform May Enhance Gene Activity to Therapeutic Levels

October 1st, 2021
Holy Trinity Student and Staff Bake to Raise Funds for HAE

September 30th, 2021
Cycle Launches Sajazir as Treatment Option for Acute HAE Attacks

September 13th, 2021
Cycle Pharmaceuticals Launches Cycle Vita™, a Dedicated Support Platform for Rare Disease Patients

August 30th, 2021
Living with hereditary angioedema (HAE)

August 29th, 2021
7 Questions to Ask Your Doctor About Hereditary Angioedema

August 26th, 2021
Phase 2 Trial of Oral KVD824 in Preventing HAE Attacks to Open

August 19th, 2021
Potential Blood Biomarkers for Types of Angioedema Noted in Study

August 18th, 2021
Your FAQs, Answered: What Is a Hereditary Angioedema Attack?

August 12th, 2021
Takhzyro With Long-term Use Safely Prevent HAE Attacks, Study Finds

August 5th, 2021
Final Results from the Longest Hereditary Angioedema Study of Active Treatment Duration Conducted to Date Support the Sustained Safety and Efficacy of TAKHZYRO® (lanadelumab) Injection for Long-Term Prevention of Hereditary Angioedema Attacks

August 5th, 2021
FDA Approves Combo Kit for Easier At-home Use of Berinert

August 2nd, 2021
Pharvaris Expanding PHVS416 Trial to US, Launching 2nd Study

July 22nd, 2021
Deal Struck to Distribute Ruconest in Middle East, North Africa

July 19th, 2021
Early Phase 1 Data Support PHA121 as Oral HAE Prophylactic

July 15th, 2021
Understanding and Managing Hereditary Angioedema Triggers

July 12th, 2021
KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE

July 12th, 2021
Interim Data Support Long-term Safety of Orladeyo for HAE Attacks

July 10th, 2021
New data from the Phase 3 HELP Study™ Open Label Expansion to evaluate the safety and efficacy of TAKHZYRO® (lanadelumab) in patients with hereditary angioedema will be announced at the European Society of Allergy and Clinical Immunology (EAACI) Hybrid Co

July 10th, 2021
America Recognizes Chronic Disease Day 2021 with Good Days

July 10th, 2021
Berotralstat Reduces Hereditary Angioedema Attacks in Phase 3 Trial

July 10th, 2021
BioCryst Reports 96-week Data from APeX-2 Showing ORLADEYO®(berotralstat) Reduced HAE Attack Rate by 80 Percent from Baseline

July 10th, 2021
BioCryst Reports 96-week Data from APeX-2 Showing ORLADEYO®(berotralstat) Reduced HAE Attack Rate by 80 Percent from Baseline

July 9th, 2021
Boston Bridges Light Up Orange & White for Chronic Disease Day & Good Days

July 9th, 2021
Children's Book Series Helps Kids Cope with Hereditary Angioedema

July 8th, 2021
Companies Join to Advance OTL-105, Potential Gene Therapy for HAE

July 1st, 2021
Orchard Therapeutics Inks Strategic Deal to Develop HSC Gene Therapy for Hereditary Angioedema

June 30th, 2021
Psychosocial burden of type 1 and 2 hereditary angioedema: A single-center Canadian cohort study

June 28th, 2021
In Major CRISPR Milestone, INTELLIA Successfully Edits Genes Inside Body

June 14th, 2021
Oral PHA121 May Lead to Faster, More Durable Effects Than Firazyr

June 11th, 2021
New Children’s Book Series Helps Kids Cope with Ultra-Rare Chronic Condition

June 5th, 2021
KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop

May 25th, 2021
BioCryst's persistence for patient insights leads to a bigger market for HAE drug Orladeyo

May 24th, 2021
Pharma, Patient Associations Join Efforts for HAE Awareness Day

May 18th, 2021
Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema

May 17th, 2021
Pharming celebrates the 10th annual "hae day :-)

May 10th, 2021
Japanese Researchers Identify New Gene Mutation Linked to HAE

May 10th, 2021
The Genetics of Hereditary Angioedema: A Review

May 9th, 2021
The Genetics of Hereditary Angioedema: A Review

May 3rd, 2021
Orladeyo Approved in EU as 1st Oral Treatment to Prevent HAE Attacks

April 29th, 2021
Supporters ‘Take Next Step’ Toward HAE Awareness Day on May 16

April 23rd, 2021
Prophylactic treatment in hereditary angioedema is associated with reduced anxiety in patients in Leipzig, Germany

April 19th, 2021
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

April 13th, 2021
Impact of lanadelumab on health related quality of life in patients with hereditary angioedema in the HELP study

April 12th, 2021
Life Quality Gains Evident With Newer Preventive HAE Therapies, Survey Finds

March 29th, 2021
Ionis reports positive topline Phase 2 study results of its novel antisense treatment for hereditary angioedema

March 23rd, 2021
C1 Inhibitor Use May Safely Prevent HAE Attacks in Pregnant Women

March 22nd, 2021
Intellia Seeks to Advance Its Gene-editing Therapy to Human Trials

March 18th, 2021
Orladeyo Now Available in France Via Early Access Program

March 17th, 2021
Patient-researcher collaboration proves to be a win-win, Japanese study shows

March 12th, 2021
Takeda Submits New Drug Application in Japan for Lanadelumab as a Preventive Treatment for Hereditary Angioedema Attacks

March 11th, 2021
Recurrent and acute abdominal pain as the main clinical manifestation in patients with hereditary angioedema

March 11th, 2021
Screening for Plasminogen Mutations in Hereditary Angioedema Patients Genes Article MDPI

March 11th, 2021
Biocryst’s berotralstat granted early access for HAE in France

March 11th, 2021
Orphan product designation requests climb in the US, remain steady in the EU

March 11th, 2021
First Patient Dosed in Phase 2 Trial Testing PHVS416 for HAE Attacks

March 8th, 2021
Interim Trial Data of Gene-editing Therapy NTLA-2001 Expected This Year

March 5th, 2021
Long-term Haegarda Found to Improve Quality of Life in HAE Patients

March 3rd, 2021
BioCryst Pharma (BCRX) Submits MAA for UK Approval of ORLADEYO, an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema

March 1st, 2021
Orladeyo Recommended in EU as 1st Oral Treatment to Prevent HAE Attacks

February 26th, 2021
Single PHA121 Dose Can Block Bradykinin Effects in Healthy Volunteers

February 25th, 2021
Oral Hereditary Angioedema Treatment Provides Effective Bradykinin-Inhibiting Concentrations

February 23rd, 2021
C1 Inhibitor Use May Safely Prevent HAE Attacks in Pregnant Women

February 19th, 2021
Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE, at the AAAAI Annual Meeting

February 18th, 2021
HAE Patients in US Favored Oral Prophylactic in 2018 Survey

February 15th, 2021
Stress Can Affect Patients’ Mental Health, How They Manage Their Care

February 8th, 2021
Menopause Found to Not Worsen HAE in Most Women

February 8th, 2021
Optimal Management of HAE: Shared Decision Making

January 9th, 2021
Psychological processes in the experience of hereditary angioedema in adult patients: an observational study

December 3rd, 2020
BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients

December 1st, 2020
Fresenius Kabi Launches Icatibant Injection to Treat Acute Attacks of Hereditary Angioedema in Adults

November 20th, 2020
New Survey Finds Vast Majority of People Living with Hereditary Angioedema (HAE) Value Efficacy and Specific Correction of C1 INH Deficiency When Choosing an HAE Therapy

October 15th, 2020
KalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema Franchise

September 29th, 2020
U.S. Food and Drug Administration Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) for Prevention of Hereditary Angioedema (HAE) Attacks in Pediatric Patients

May 15th, 2020
BioCryst Celebrates HAE Patients with HAE Global Walk

May 4th, 2020
CSL Behring is Committed to Supporting Patients

May 1st, 2020
Pharming to Support Patients Continuity in Care

April 22nd, 2020
Takeda Expands Patient Assistance in the U.S. During COVID-19 Crisis

April 21st, 2020
Pharming reports encouraging results from use of RUCONEST® in COVID-19 patients

April 6th, 2020
Mensaje de la Directora de Salud de la HAEA, Lois Perry

April 6th, 2020
A Message from the Director of HAE Health Lois Perry

April 6th, 2020

March 19th, 2020
An Important Message Regarding HAEA Upcoming Events

March 18th, 2020
How Our Pharmaceutical Companies Are Managing the Coronavirus Situation.

March 6th, 2020
A Message from HAEA Nurse Case Manager Troyce Venturella

January 13th, 2020
KalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema Franchise

November 27th, 2018
JAMA Publishes Complete Results of Phase 3 HELP Study™ Evaluating Lanadelumab as a Preventive Treatment for Hereditary Angioedema

August 23rd, 2018
Shire Announces FDA Approval of TAKHZYRO™ (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema

June 21st, 2018
Shire Announces FDA Approval for Label Expansion of CINRYZE® (C1 esterase inhibitor [human]) for Prevention of Attacks in Pediatric Hereditary Angioedema Patients

May 16th, 2018
KalVista Pharmaceuticals Recognizes HAE Day

April 9th, 2018
HAEA comments on ICER HAE therapy assessment

February 25th, 2018
FDA Accepts Shire’s Biologics License Application (BLA) and Grants Priority Review for Lanadelumab for the Prevention of Attacks in Hereditary Angioedema (HAE) Patients

February 15th, 2018
Shire Announces FDA Acceptance of sBLA for CINRYZE® (C1 esterase inhibitor [human]) for Pediatric Hereditary Angioedema Use

January 24th, 2018
FDA Grants Approval to Shire for Technology Transfer of CINRYZE® (C1 esterase inhibitor [human]) Drug Product Manufacturing Process to Vienna, Austria Manufacturing Site

January 22nd, 2018
BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine Capabilities to Serve More Patients with Rare Diseases

January 8th, 2018
A Big Pharma-funded charity that helps patients pay for drugs just sued the government

January 5th, 2018
KalVista Pharmaceuticals Commences Two Clinical Trials

September 29th, 2017
RUCONEST® provided clinically meaningful relief of symptoms in children with hereditary angioedema

September 14th, 2017
KalVista Pharmaceuticals Reports Fiscal First Quarter Results

September 11th, 2017
Shire’s Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces Hereditary Angioedema Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial

September 11th, 2017
Pharming announces conclusion of FDA End of Phase 2 interactions on RUCONEST® for Prophylaxis of HAE

September 5th, 2017
BioCryst Announces Positive Results from its APeX-1 Phase 2 Trial in HAE

July 26th, 2017
Pharming announces publication of RUCONEST® prophylactic data in The Lancet

July 23rd, 2017
FDA Approves HAEGARDA® King Of Prussia, PA

June 22nd, 2017
FDA Approves First Subcutaneous C1 Esterase Inhibitor To Treat Rare Genetic Disease

May 24th, 2017
Attune Pharmaceuticals Announces Positive Data from Recent Pre-Clinical Studies for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at C1-INH Deficiency Workshop

May 24th, 2017
Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial

April 13th, 2017
BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks

March 23rd, 2017
New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring’s Subcutaneous C1-Esterase Inhibitor in HAE Patients

October 1st, 2016
Elucidating the Mechanism of Gain of Toxic Function From Mutant C1 Inhibitor Proteins in Hereditary Angioedema

April 12th, 2016
How we manage persons with hereditary angioedema

Single PHA121 Dose Can Block Bradykinin Effects in Healthy Volunteers